BTIM Corp. continued to hold its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,425 shares of the company’s stock at the end of the second quarter. BTIM Corp.’s holdings in Henry Schein were worth $261,000 at the end of the most recent reporting period.
A number of other large investors have also made changes to their positions in HSIC. Bluestein R H & Co. raised its position in shares of Henry Schein by 22.5% in the first quarter. Bluestein R H & Co. now owns 123,224 shares of the company’s stock valued at $20,944,000 after buying an additional 22,608 shares during the last quarter. BlackRock Inc. raised its position in shares of Henry Schein by 2,999.6% in the first quarter. BlackRock Inc. now owns 5,595,279 shares of the company’s stock valued at $951,028,000 after buying an additional 5,414,761 shares during the last quarter. Chevy Chase Trust Holdings Inc. raised its position in shares of Henry Schein by 1.4% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 269,458 shares of the company’s stock valued at $45,800,000 after buying an additional 3,699 shares during the last quarter. Azimuth Capital Management LLC raised its position in shares of Henry Schein by 4.9% in the first quarter. Azimuth Capital Management LLC now owns 36,234 shares of the company’s stock valued at $6,159,000 after buying an additional 1,705 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Henry Schein by 0.6% in the first quarter. Dimensional Fund Advisors LP now owns 310,134 shares of the company’s stock valued at $52,714,000 after buying an additional 1,831 shares during the last quarter. 90.60% of the stock is owned by hedge funds and other institutional investors.
Shares of Henry Schein, Inc. (NASDAQ:HSIC) traded down 0.07% during mid-day trading on Friday, hitting $169.49. The company’s stock had a trading volume of 525,408 shares. Henry Schein, Inc. has a 1-year low of $146.23 and a 1-year high of $186.99. The company has a 50-day moving average of $179.49 and a 200 day moving average of $175.49. The company has a market cap of $13.40 billion, a price-to-earnings ratio of 24.77 and a beta of 1.09. Henry Schein shares are scheduled to split before the market opens on Friday, September 15th. The 2-1 split was announced on Wednesday, August 16th. The newly minted shares will be payable to shareholders after the market closes on Thursday, September 14th.
Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings results on Tuesday, August 8th. The company reported $1.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.73 by $0.02. The business had revenue of $3.06 billion during the quarter, compared to analysts’ expectations of $3.05 billion. Henry Schein had a return on equity of 19.91% and a net margin of 4.59%. The firm’s revenue for the quarter was up 6.4% compared to the same quarter last year. During the same period in the previous year, the company posted $1.64 earnings per share. On average, analysts expect that Henry Schein, Inc. will post $7.27 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This article was first published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.com-unik.info/2017/08/19/btim-corp-has-261000-stake-in-henry-schein-inc-nasdaqhsic-updated-updated-updated.html.
Several brokerages have weighed in on HSIC. Jefferies Group LLC reaffirmed a “hold” rating and issued a $177.00 target price on shares of Henry Schein in a research report on Friday, July 21st. Zacks Investment Research raised Henry Schein from a “hold” rating to a “buy” rating and set a $190.00 target price on the stock in a research report on Tuesday, April 25th. Stifel Nicolaus reaffirmed a “hold” rating on shares of Henry Schein in a research report on Thursday, July 6th. Barrington Research increased their price objective on Henry Schein from $196.00 to $198.00 and gave the company an “outperform” rating in a report on Wednesday, May 10th. Finally, Northcoast Research raised Henry Schein from a “neutral” rating to a “buy” rating and set a $218.00 price objective on the stock in a report on Monday, August 7th. One research analyst has rated the stock with a sell rating, ten have given a hold rating and seven have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $185.56.
About Henry Schein
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
What are top analysts saying about Henry Schein Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Henry Schein Inc. and related companies.